ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis

ClinicalTrials.gov ID: NCT01690299

Public ClinicalTrials.gov record NCT01690299. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 10:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3B, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study Of The Efficacy And Safety Of Apremilast (CC-10004), Etanercept, And Placebo, In Subjects With Moderate To Severe Plaque Psoriasis

Study identification

NCT ID
NCT01690299
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Amgen
Industry
Enrollment
250 participants

Conditions and interventions

Interventions

  • Apremilast Drug
  • Etanercept Drug
  • Placebo injection Drug
  • Placebo tablet Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2012
Primary completion
Jul 2, 2014
Completion
Apr 3, 2016
Last update posted
Mar 14, 2022

2012 – 2016

United States locations

U.S. sites
31
U.S. states
20
U.S. cities
30
Facility City State ZIP Site status
Arizona Research Center Phoenix Arizona 85023
Bakersfield Dermatology and Skin Cancer Medical Group Bakersfield California 93309
University of California Irvine-Department of Dermatology Irvine California 92697
University of California San Diego Medical Center San Diego California 92122
Horizons Clinical Research Denver Colorado 80220
George Washington University Washington D.C. District of Columbia 20037
Florida Center for Dermatology, PA Jacksonville Florida 32204
Florida Academic Dermatology Center Miami Florida 33136
International Dermatology Research Miami Florida 33144
Renstar Medical Research Ocala Florida 34471
Atlanta Dermatology, Vein and Research Center, PC Alpharetta Georgia 30022
NorthShore University HealthSystem Skokie Illinois 60077
Southern Illinois University School of Medicine Springfield Illinois 62702
Dawes Fretzin Clinical Research Group, LLC Indianapolis Indiana 46256
Dermatology and Advanced Aesthetics Lake Charles Louisiana 70605
Lawrence Green, MD, LLC Rockville Maryland 20850
Dartmouth Hitchcock Medical Center Lebanon New Hampshire 03756
Robert Wood Johnson Medical School Somerset New Jersey 08873
Forest Hills Dermatology Group Forest Hills New York 11375
NYU Department of Dermatology New York New York 10016
University of North Carolina Chapel Hill North Carolina 27516
Duke University Medical Center Durham North Carolina 27710
Wake Forest University Health Sciences Winston-Salem North Carolina 27104
University Hospitals Case Medical Center Cleveland Ohio 44106
Ohio State University Medical Center Columbus Ohio 43230
University of Pittsburgh Medical Center Pittsburgh Pennsylvania 15213
Tennesse Clinical Research Center Nashville Tennessee 37215
Teckton Research Austin Texas 78745
The Education and Research Foundation Lynchburg Virginia 24501
Virginia Clinical Research Inc Norfolk Virginia 23507
Dermatology Associates of Seattle Seattle Washington 98101

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 51 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01690299, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 14, 2022 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01690299 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →